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Abstract
Introduction: The treatment of rheumatoid arthritis (RA) patients with anti-tumor necrosis factor alpha (TNFa)
biological drugs has dramatically improved the prognosis of these patients. However, a third of the treated patients
do not respond to this therapy. Thus, the search for biomarkers of clinical response to these agents is currently
highly active. Our aim is to analyze the number and distribution of circulating monocytes, and of their CD14
+highCD16-, CD14+highCD16+ and CD14+lowCD16+ subsets in methotrexate (MTX) non-responder patients with RA,
and to determine their value in predicting the clinical response to adalimumab plus MTX treatment.
Methods: This prospective work investigated the number of circulating monocytes, and of their CD14+highCD16-,
CD14+highCD16+ and CD14+lowCD16+ subsets, in 35 MTX non-responder patients with RA before and after three
and six months of anti-TNFa treatment using multiparametric flow cytometry. The number of circulating
monocytes in an age- and sex-matched healthy population was monitored as a control.
Results: Non-responder patients with RA show an increased number of monocytes and of their CD14+highCD16-,
CD14+highCD16+ and CD14+lowCD16+ subsets after three months of adalimumab plus MTX treatment that
remained significantly increased at six months. In contrast, significant normalization of the numbers of circulating
monocytes was found in responders at three months of adalimumab plus MTX treatment that lasts up to six
months. CX3CR1 expression is increased in monocytes in non-responders. At three months of anti-TNFa treatment
the number of circulating monocytes and their subsets was associated with at least 80% sensitivity, 84% specificity
and an 86% positive predictive value (PPV) in terms of discriminating between eventual early responders and non-
responders.
Conclusions: The absolute number of circulating monocytes and of their CD14+highCD16-, CD14+highCD16+ and
CD14+lowCD16+ subsets at three months of adalimumab plus MTX treatment, have a predictive value (with high
specificity and sensitivity) in terms of the clinical response after six months of anti-TNFa treatment in patients with RA.
Introduction
Dramatic improvements in the management of patients
with rheumatoid arthritis (RA) have been achieved in
the last two decades. The possibilities of controlling dis-
ease progression and joint destruction have greatly
increased through the use of biological drugs with
tumor necrosis factor alpha (TNFa) blockade activity
[1,2]. In addition, new biologic therapies with different
targets, such as interleukin (IL)-6, CD20, have shown
relevant effectiveness in the control of RA [3,4]. This
expansion in the number of effective therapies is also
accompanied by a growing evidence of wide variation in
the RA patient clinical response to these biological
therapies [5]. The prevention of delays in the use of the
most effective treatment for each patient, the avoidance
of unnecessary secondary effects and the rational use of
scant economic resources have all stimulated the search
for biomarkers that predict the response of individuals
to different RA treatments.
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Monocytes are bone marrow-derived cells that med-
iate essential regulatory and effector functions in innate
and adaptative immunity [6]. Circulating peripheral
blood monocytes may migrate into tissues where they
differentiate into different effector cells, such as macro-
phages, dendritic cells and osteoclasts [6-9]. The circu-
lating monocyte compartment is phenotypically and
functionally heterogeneous. Three major subsets based
on the expression of CD14 (the lipopolysaccharides
(LPS) co-receptor) and CD16 (the FcgRIII low affinity
immunoglobulin G (IgG) receptor) have been defined in
circulating monocytes [6,8-10]. The majoritarian subsets
or “classic” monocytes are phenotypically defined by an
intense expression of CD14, but lack CD16 (CD14
+highCD16-). The minoritarian subsets (10% of the circu-
lating monocytes) are characterized by the expression of
CD16 plus either high or low levels of CD14 (intermedi-
ate CD14+highCD16+ monocytes and CD14+lowCD16+
non-classical monocytes, respectively) [11]. These three
phenotypically defined monocyte subsets show different
functional properties, such as patterns of cytokine secre-
tion and chemokine receptor expression, and migratory
properties into normal and inflamed tissue. Further-
more, these three different monocyte subsets also differ
in their ability to differentiate into effector cells, includ-
ing macrophages, dendritic cells and osteoclasts [8-10].
Monocytes and monocyte derived cells appear to be
involved in the pathogenesis of RA [12,13].
Roughly, 20 to 30% of RA patients show unresponsive-
ness to anti-TNFa biological therapy [14,15]. These ther-
apeutic failures may occur early after the start of
treatment or late in a secondary phase that develops in
initial responders during the course of therapy [16]. The
latter appears to be related to the formation of anti-drug
antibodies (anti-anti-TNFa antibodies) in a subset of
patients [17]. However, the mechanism of early anti-
TNFa treatment resistance remains elusive. Thus, the
hypothesis tested in this work was that the pre-treatment
absolute number, distribution and migratory properties
of circulating monocytes, and of their CD14+highCD16-,
CD14+highCD16+ and CD14+lowCD16+ subsets, might
help predict the early therapeutic response to anti-TNFa
biological therapy. The number of CD14+highCD16-,
CD14+highCD16+ and CD14+lowCD16+ monocytes was
prospectively investigated in patients with RA before
initiation of anti-TNFa therapy and during the first six
months of anti-TNFa treatment. Furthermore, and with
respect to active naive RA patients and healthy donors,
we investigated the pattern of circulating monocyte sub-
sets in patients with active RA before starting treatment
with adalimumab plus MTX. This allowed the potential
link between the activity of the disease and the pattern of
abnormality in this cellular compartment to be studied.
Materials and methods
Inclusion and exclusion criteria
Thirty-five patients visiting the Immunology and Rheu-
matology Service at the Hospital Universitario Príncipe
de Asturias (HUPA) were enrolled in the study. All gave
their informed consent to be included; the study was
approved by the hospital’s clinical ethics committee.
Patients were studied in parallel with sex- and age-
matched healthy controls.
Inclusion criteria
The entry criteria included patients who had: 1) a diag-
nosis of RA according to the 1987 revised European
League Against Rheumatism (EULAR) criteria with an
of age higher than 18 years [18]; 2) a disease activity
score 28 (DAS28) according to EULAR criteria of more
than 2.5 [18]; and 3) to be treated with weekly MTX (15
to 20 mg per week) for at least the previous three
months.
Exclusion criteria
The exclusion criteria for this study included severe car-
diovascular disease (congestive heart failure, uncontrolled
hypertension, coronary disease, severe arrhythmia),
hematopoietic, lung, hepatic or renal disorders not
related to the RA, diabetes mellitus, active bacterial or
viral infections, other autoimmune diseases, treatment
with glucocorticoids, immunosuppressors or other drugs
that interact with the immune system in the previous
three months, treatment with steroids in the previous
month, possible pregnancy or lactation during the six-
month study period, simultaneous malignancy, malnutri-
tion and congenital immunodeficiency.
We also included in the study 13 patients who were
age ≥18 years, had a diagnosis of RA according to the
1987 revised European League Against Rheumatism
(EULAR) criteria [18], had a Disease Activity Score 28
(DAS28) according to EULAR criteria of more than 2.5
[18], and were untreated with disease-modifying anti-
rheumatic drugs (DMARDS).
Study protocol
All patients were treated weekly for at least three
months with 15 to 20 mg MTX (orally) plus 20 mg folic
acid the next day and adalimumab 40 mg every other
week. Patients were also advised to take non-steroidal
anti-inflammatory drugs at fixed doses during the study.
All were monitored monthly for clinical and analytical
tolerance to MTX and adalimumab treatment and at
three and six months to assess clinical response and to
undertake immunological studies. Disease activity was
determined by the DAS28 score according to EULAR
criteria and using a validated Spanish version of the
Health Assessment Questionnaire (HAQ) [19]. The clin-
ical response of the patients to MTX plus adalimumab
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treatment was defined according to EULAR criteria for
RA [18], classifying patients as responders or non-
responders. The responder group included those
patients with a DAS28 score of < 2.6 after six months of
MTX plus adalimumab treatment, plus those whose
DAS28 score decreased by at least 1.2 with respect to
the initial value.
Three peripheral blood samples were taken from each
patient by antecubital venipuncture at baseline (before
starting adalimumab treatment), at three months of
treatment and at six months of treatment.
Isolation of peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMC) were sepa-
rated out by Ficoll-Hypaque (Lymphoprep™, Axis-Shield,
Oslo, Norway) gradient centrifugation [20]. They were
then resuspended in Roswell Park Memorial Institute
medium (RPMI) 1640 (Biowhittaker Products, Verviers,
Belgium) supplemented with 10% heat-inactivated fetal
calf serum, 25 mM Hepes (Biowhittaker Products) and 1%
penicillin-streptomycin (Biowhittaker Products). Cell enu-
meration was performed by conventional light microscopy
using a Neubauer chamber following trypan blue dead cell
exclusion criteria. The viability of fresh PBMC was
checked by both trypan blue (light microscopy) and 7-ami-
noactinomycin D (7-AAD) (flow cytometry) exclusion.
Immunophenotype studies
For immunofluorescent staining, fresh monocytes were
incubated with a combination of fluorescein (FITC), phy-
coerythrin (PE), peridinin chlorophyll protein conjugate
(PerCP), and Alexa Fluor-647-labeled monoclonal antibo-
dies (MoAbs). The MoAbs were used in a four-color com-
bination (FITC/PE/PerCP/Alexa Fluor-647): CX3CR1/-/
CD14/CD16. Control studies with unstained cells and
cells incubated with isotype-matched irrelevant FITC-,
PE-, PerCP and Alexa Fluor-647-labeled MoAbs were
performed for each experiment. For these procedures,
anti-CD14 and anti-CD16 were purchased from Becton
Dickinson (Franklin Lakes, NJ, USA) and anti-CX3CR1
purchased from MBL, Medical and Biological Laboratories
Co., Ltd (Naka-ku Nagoya, Japan). Cell acquisition and
four-color immunofluorescence analyses were performed
using a FACSCalibur flow cytometer (Becton Dickinson)
running CellQuest Pro (Becton Dickinson) and FlowJo
software (Tree Star, Inc., Ashland, OR, USA), respectively.
In the FSC-SSC dot plot, a biparametric gate was drawn
around the monocyte population. The absolute number of
circulating monocyte subsets was calculated by the
percentage of each subpopulation in peripheral blood
determined by flow cytometry multiplied by the total
number of monocytes per microliter measured by Beck-
man Coulter, Inc. (Brea, CA, USA).
Statistical analysis
Variables with nominal scale are described using absolute
and relative frequencies. The Kolmogorov-Smirnov test
was employed to verify the normality of distribution of
continuous variables. For univariate description of
normally distributed clinical variables, mean values and
standard deviation (SD) are given. The differences in
demographic characteristics were assessed using Pearson’s
chi-squared tests, Fisher’s exact test, Student’s t-tests or
ANOVA with Bonferroni post-hoc adjustment for multi-
ple testing. The results of the immunophenotype studies
were expressed as mean and the standard error of the
mean (SEM). Comparisons among healthy controls,
responders and non-responders at baseline, were carried
out using the Kruskal-Wallis test or ANOVA test for dif-
ferent samples. We used a two-sided analysis of variance
(ANOVA) with Bonferroni adjustment to evaluate longitu-
dinal changes. To assess the value of baseline circulating
monocytes and their different subsets as predictors of
MTX treatment response at six months of follow-up,
receiver operating characteristic (ROC) curve analyses
were performed, and the respective areas under the curves
(AUC) were determined as measures of overall perfor-
mance. The best predictive cut-off value was defined as
that which gave the highest product of sensitivity and spe-
cificity, positive predictive value (PPV) and negative pre-
dictive value (NPV). All analyses were performed using
the Statistical Package for the Social Sciences (SPSS,
version 19.0, Chicago, IL, USA). Significance was set at
P < 0.05.
Results
Demographic characteristics of the patients
Table 1 shows the baseline characteristics of the 23
responders and 12 non-responders included in the ana-
lysis. No significant differences were seen between these
groups of patients with respect to age or sex distribu-
tion, nor in the clinical or analytical variables studied.
Non-responder RA patients show increased number of
monocytes and of their CD14+highCD16-, CD14+highCD16+
and CD14+lowCD16+ subsets after three months of anti-
TNFa treatment
Next, we investigated the absolute number of circulat-
ing monocytes, and those of the CD14+highCD16-,
CD14+highCD16+ and CD14+lowCD16+ subsets were
studied in all 35 MTX-treated patients before starting
adalimumab plus MTX treatment, and again at three
and six months.
Figure 1 shows that the absolute number of circulating
monocytes in the non-responders was significantly
higher than in the responders at three months of adali-
mumab plus MTX treatment. The absolute number of
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monocytes in the non-responders remained significantly
increased with respect to responders and healthy con-
trols until the six-month study period. In contrast, sig-
nificant normalization of the numbers of circulating
monocytes was found in responders at three months of
anti-TNFa treatment that lasts up to six months. We
did not find significant differences between responders
and non-responders at baseline but both were signifi-
cantly higher with respect to healthy donors.
The non-responders also had significantly higher num-
bers of circulating monocytes and their CD14+CD16-,
CD14+highCD16+ and CD14+lowCD16+ subsets than
healthy controls at baseline and all over the six months
of anti-TNFa treatment. However, significant differences
between responders and non-responders appeared at
three months and remained until the end of the study of
adalimumab plus MTX treatment for CD14+CD16- and
CD14+highCD16+ subsets. In contrast, the number of cir-
culating CD14+lowCD16+monocytes was significantly
increased in non-responder patients with respect to
healthy donors and responders at baseline and along the
six months of study. No significant differences were
found between responders and healthy controls in the
absolute number of CD14+CD16-, CD14+highCD16+ and
CD14+lowCD16+ subsets at any time of the study but the
CD14+lowCD16+ subset was significantly increased in
responder patients at baseline.
Non-responders show progressive redistribution of the
monocyte subsets
Figure 2 shows the distribution of the CD14+highCD16-,
CD14+highCD16+ and CD14+lowCD16+ monocyte subsets in
the patients and healthy controls. Responders and non-
responders showed a significantly smaller percentage of
CD14+highCD16- monocytes at baseline with respect to
healthy donors but they showed a reverse pattern of
response to anti-TNFa treatment. Non-responders showed
a progressive decrease of the percentage of CD14+hihCD16+
monocyte subset along the study period. In contrast,
responders presented a progressive increase of the
percentage of CD14+highCD16+ monocyte subset that
reached healthy controls values at three months of adali-
mumab plus MTX treatment and was significantly higher
with respect to non-responder at six months of treatment.
The number of circulating monocytes, and of their
CD14+highCD16-, CD14+highCD16+ and CD14+lowCD16+
subsets, predicts the clinical response to anti-TNFa at
three months of treatment
We studied the predictive value of the absolute number
of circulating monocytes, and of their CD14+highCD16-,
CD14+highCD16+ and CD14+lowCD16+ subsets, with
respect to clinical response to adalimumab plus MTX.
At baseline, we did not find that these biological mar-
kers show significant predictive value of the early
response to anti-TNFa therapy (Figure 3). However, at
three months of adalimumab plus MTX treatment, a
cut-off value of 650 cells/μl for circulating monocytes
was associated with 80% sensitivity, 100% specificity and
a 100% PPV in terms of discriminating between eventual
early responders and non-responders. A cut-off value of
502 cells/μl for the CD14+highCD16- cell subset was
associated with 80% sensitivity, 100% specificity and
100% PPV in terms of discriminating between eventual
responders and non-responders. A cut-off value of 54
cells/μl for the CD14+highCD16+ cell subset and of 19
cells/μl for the CD14+lowCD16+ subset was associated
with 80% and 100% sensitivity, 84% and 84% specificity,
and 100% and 83% PPV, in terms of discriminating
between eventual responders and non-responders.
CX3CR1 expression is increased in monocytes in non-
responders
The expression of CX3CR1 was determined in the three
monocyte subsets in both patients and healthy controls
(Figure 4). At baseline, the expression of CX3CR1 in the
CD14+lowCD16+ monocyte subset from responder and
non-responders was similar and showed no significant
differences with respect to healthy controls. A progres-
sive and significant increase in CX3CR1 expression was
Table 1 Demographic, clinical and biological data of the patients at baseline
Variables MTX active (n = 13)
(mean ± SD)
Responders (n = 23)
(mean ± SD)
Non-responders (n = 12)
(mean ± SD)
P-value
Age (years) 51.64 ± 10.88 50.36 ± 5.82 52.25 ± 11.09 .762
Sex (men/women) 38.46%/61.54% 33.33%/66.67% 37.50%/62.50% .809
CRP (mg/dl) 16.61 ± 7.21 14.33 ± 14.10 11.68 ± 10.74 .569
Rheumatoid factor (+/-) 92.30%/7.70 80.00%/20.00% 62.50%/37.50 .283
Anti-CCP (UI/ml) 423.25 ± 296.01 994.60 ± 620.24 329.50 ± 7.50 .075
DAS28 3.71 ± .71 2.64 ± .84 3.20 ± .88 .090
Erosions (+/-) 30.76%/69.24% 60.00%/40.00% 71.40%/28.60% .518
Onset of Symptoms (months) 9.60 ± 9.10 100.53 ± 66.14 148.14 ± 77.79 .090
HAQ .78 ± .53 1.18 ± .47 1.31 ± .72 .553
Anti-CCP, anti-cyclic citrullinated peptide antibody; CRP, C-reactive protein; DAS28, Disease Activity Score 28; HAQ, Health Assessment Questionnaire
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observed in this monocyte subset in non-responders
after three and six months of treatment. In contrast, the
expression of CX3CR1 in CD14+highCD16- and CD14
+highCD16+ monocyte subsets was significantly increased
in non-responder patients at baseline and over the study
period. No significant differences in the CX3CR1
expression were seen among CD14+highCD16-, CD14
+highCD16+ and CD14+lowCD16+monocytes from
responders and healthy controls.
Similar numbers and pattern of distribution of
monocytes and their CD14+highCD16-, CD14+highCD16+
and CD14+lowCD16+ subsets in naive and MTX active
patients with RA
We investigated the absolute number of circulating
monocytes, and those of the CD14+highCD16-, CD14
+highCD16+ and CD14+lowCD16+ subsets as well as their
frequencies of 13 active naive patients with RA, 35
MTX active RA patients and 15 healthy controls. There
Figure 1 Percentage of circulating monocytes in patients with RA at baseline and over anti-TNFa treatment. The absolute number
(cells/μl) of circulating monocytes (panel A), CD14+highCD16- (panel B), CD14+highCD16+ (panel C) and CD14+lowCD16+ monocytes (panel D) of
non-responders (□) and responders (○) at baseline and after three and six months of MTX treatment, and of healthy controls (▼), are shown as
the mean ± SEM. * significant difference between patients with RA and healthy controls. † significant difference between non-responders and
responders. ‡ significant difference between baseline and six-month values.
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were no significant differences in the absolute number
and distribution of circulating monocytes and their sub-
sets between naive and MTX active patients with RA
(Additional files 1 and 2).
Discussion
This work shows that the absolute number of circulating
monocytes, and of their CD14+highCD16-, CD14
+highCD16+ and CD14+lowCD16+ subsets at three
months of adalimumab plus MTX treatment, have a
predictive value (with high specificity and sensitivity) in
terms of the clinical response after six months of anti-
TNFa treatment in patients with RA. Furthermore, the
pattern of abnormal redistribution of circulating mono-
cyte subsets is similar in naive and MTX-treated active
RA patients.
Figure 2 Percentage of monocyte subsets in patients with RA at baseline and over anti-TNFa treatment. Panel A represents flow cytometry
analysis of circulating monocytes from a representative patient. The percentage of circulating CD14+highCD16- (panel B), CD14+highCD16+ (panel C)
and CD14+lowCD16+ monocytes (panel D) of non-responder (□) and responders (○) at baseline and after three and six months of MTX treatment, and
those of healthy controls (▼), are shown as mean ± SEM. * significant difference between patients with RA and healthy controls. † significant difference
between non-responders and responders. ‡ significant difference between baseline and six-month values.
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Figure 3 Receiver-operating characteristic (ROC) analysis of the absolute numbers of circulating monocytes and their subsets. Receiver-
operating characteristic (ROC) analysis of the absolute numbers of circulating monocytes, and their CD14+highCD16-, CD14+highCD16+ and CD14
+lowCD16+ subsets, at three months of anti-TNFa treatment (A, B, C and D, respectively). The predictive value of the absolute numbers of
monocytes was determined by calculating the area under the curve (AUC). The optimum cut-offs (cells/μl) to distinguish MTX responders from
non-responders, plus their sensitivity (Sens), specificity (Spec), positive predictive value (PPV), negative predictive value (NPV) and likelihood ratio
(LR), are illustrated next to the curves. These were used to verify the validation of the ROC curves and to establish the predictive power of the
cut-offs.
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The treatment of RA patients with anti-TNFa biologi-
cal drugs has dramatically improved the prognosis of
these patients. However, a third of the treated patients
do not respond to this therapy [14,15,21]. Thus, the
search for biomarkers of clinical response to these
agents is currently highly active. Most studies have
explored the utility of genetics and autoantibody profil-
ing to predict response to anti-TNFa therapies in RA
without satisfactory results for potential clinical use [16].
A number of other potential therapeutic response bio-
markers have been studied. Down-regulation of expres-
sion of a number of proinflammatory genes, including
Figure 4 CX3CR1 expression on circulating monocyte subsets in patients with RA at baseline and over anti-TNFa treatment. The mean
fluorescence intensity (MFI) of CX3CR1 in circulating CD14+highCD16- (panel A), CD14+highCD16+ (panel B) and CD14+lowCD16+ monocytes (panel
C) of non-responders (□) and responders (○) at baseline and after three and six months of MTX treatment, as well as those of healthy controls
(▼), are shown as means ± SEM. Panel D is a histogram of CX3CR1 for circulating CD14+highCD16- monocytes from a representative responder
and non-responder at six months of treatment. * Significant difference between patients and healthy controls. † Significant difference between
non-responders and responders. ‡ Significant difference between baseline and six-month values.
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IL-1b, IL-8 and TNFAIP3, in peripheral blood mono-
nuclear cells 72 h after the first dose of etanercept was
associated with low sensitivity and specificity to a good
clinical response during the first three months of treat-
ment [22]. In addition, pretherapy CD11c gene expres-
sion on monocytes was increased in responder patients
to adalimumab alone [23]. At the synovium level, the
inflammatory infiltration with organized lymphocyte
aggregate pattern, which may include germinal centers,
has been associated with a better response to infliximab
at 16 weeks [24]. Other authors have suggested that
characterization of the pattern autoantibodies, serum or
PBMCs’ expression of cytokine levels show differences
between responders and nonresponders to etanercept
treatment in patients with RA [25,26]. However, at pre-
sent, no robust biomarker for anti-TNFa treatment has
been identified for the routine in clinical practice in RA
patients. The present study, therefore, investigated the
potential value of circulating monocytes, a readily acces-
sible blood compartment, for predicting the clinical
response of patients with RA to adalimumab plus MTX.
The selection of these cells is based on the critical role
that monocytes and tissular monocyte-driven cells plays
in the induction of damage at inflamed joints and other
tissues lesions [12]. The inflammatory role of circulating
monocytes has been related to their ability to migrate to
inflamed tissues, to provide effector functions such as
cytokine and chemokine production, to undertake pha-
gocytosis and oxidative radical generation, and to their
ability to differentiate into different effector cells such as
osteoclasts and dendritic cells [6,7]. Our data show that
the absolute number of circulating monocytes, and of
their CD14+highCD16-, CD14+highCD16+ and CD14
+lowCD16+ subsets after three months of treatment with
adalimumab plus MTX, have a highly predictive value of
the clinical response after six months of treatment iden-
tifying those patients with an early treatment resistance
to this anti-TNFaagent.
The explanation of this observed relevance of circulat-
ing monocytes as biomarkers of adalimumab response
in RA patients has been not established. However, our
data support that the absolute number of the monocyte
subsets play a role in the activity of the disease and in
the response to adalimumab plus MTX. Our data show
that the number and distribution of the monocyte sub-
sets in naive and MTX treated active RA patients is
similar. However, the treatment with MTX plus adali-
mumab discriminates two patterns of behavior of the
monocytic compartment in RA patients. In adalimumab
responders, the number of the circulating monocyte
subsets normalize at three months of treatment and
remain similar along the study period. In contrast, in
non-responders the significant increase in the pre-treat-
ment number of monocytes and of their subsets remains
the same or even increases along the treatment. This
heterogeneity in the behavior monocyte compartment
cannot be ascribed to different activity of the disease
because it was similar in both responders and nonre-
sponders at the beginning of the treatment. Thus, adali-
mumab plus MTX treatment in responder patients is
able to show an immunomodulatory effect with a drastic
reduction in the number of the three monocyte subsets.
Interestingly, in experimental models of RA, the deple-
tion of circulating monocytes or synovial macrophages
is associated with control of the joint inflammation and
disease [27,28]. In addition, it has been reported that a
third of the patients with RA with synovial effusions dis-
plays a peripheral blood monocytosis [29].
The mechanisms of the therapeutic effects of anti-
TNFa on RA have not been fully established [30]. It has
been shown that anti-TNFa treatment induces effects at
different levels of the immunoinflammatory response,
including cell trafficking reducing chemotaxis and/or
leukocyte adhesion to the inflamed endothelium [31,32]
and modulation of soluble mediators [33]. Interestingly,
anti-TNFa agents induce apoptosis of circulating and
synovial fluid monocytes in RA patients [34,35]. In addi-
tion, in RA responder patients, gene expression profiling
analysis of circulating monocytes shows a decrease of
chemoattractants and adhesions molecules associated
with anti-TNFa treatment [36]. Furthermore, the
increased number of synovial sublining macrophages is
a biomarker of anti-TNFa treatment in RA [37,38]. In
agreement, our data clearly support that adalimumab
plus MTX treatment induces a marked decrease in cir-
culating monocytes in responder RA patients. Moreover,
we also found an increased CX3CR1 expression of cir-
culating monocytes in non-responders. This chemokine
receptor is involved in the regulation of the monocyte
tissue migration. Several mechanisms might be involved
in the induction of this effect of adalimumab plus MTX
on circulating monocytes, including modulation of cell
trafficking, monocyte survival and/or systemic genera-
tion from bone marrow precursors. The cause of the
lack of effect of adalimumab in circulating monocytes of
nonresponders remains unknown. The described dose
dependence of the proapoptotic effect of anti-TNFa on
monocytes [30] might suggest a potentially insufficient
administration of adalimumab in non-responders,
although a non-discovered mechanism of resistance can
be also involved. These contrasting observations on
apoptosis-related genes illustrated the complexity of the
regulation of this process in inflammatory disease.
Moreover, clinical responders to infliximab or etaner-
cept had a greater increase in synovial apoptosis than
did clinical non-responders [34,39].
The observed predictive value at three months of the
absolute number of circulating monocytes, and of their
Chara et al. Arthritis Research & Therapy 2012, 14:R175
http://arthritis-research.com/content/14/4/R175
Page 9 of 11
CD14+highCD16-, CD14+highCD16+ and CD14+lowCD16+
subsets, in terms of clinical response to adalimumab
plus MTX treatment in patients with RA requires con-
firmation in large multicenter studies including patients
belonging to different races. The analysis of this biomar-
ker with other anti-TNFa agents is also required. How-
ever, the number of monocytes, and of their CD14
+highCD16-, CD14+highCD16+ and CD14+lowCD16+ sub-
sets, in peripheral blood would appear to be a practical
biomarker for predicting the response to adalimumab
plus MTX in patients with RA.
Conclusions
In summary, this study shows that the absolute number
of circulating monocytes, and of their CD14+highCD16-,
CD14+highCD16+ and CD14+lowCD16+ subsets at three
months of anti-TNFa treatment, have a predictive value
in terms of the clinical response after six months of
anti-TNFa treatment in patients with RA. Indeed, non-
responder patients with RA show an increased number
of monocytes and of their CD14+highCD16-, CD14
+highCD16+ and CD14+lowCD16+ subsets after three
months of anti-TNFa treatment. In addition, non-
responders show progressive redistribution of the mono-
cyte subsets as well as an increased expression of
CX3CR1. Thus, the number of monocytes, and of their
CD14+highCD16-, CD14+highCD16+ and CD14+lowCD16+
subsets, in peripheral blood would appear to be a practi-
cal biomarker for predicting the response to anti-TNFa
in patients with RA.
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untreated naive and MTX-treated active patients with RA and of healthy
controls, are shown as the mean ± SEM. * Significant difference between
patients with RA and healthy controls.
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